[{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Arnasi Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ceftazidime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Arrevus \/ Arnasi Group","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Arnasi Group"},{"orgOrder":0,"company":"Aceragen","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sodium Fusidate","moa":"||Elongation factor G","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aceragen \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Idera Pharmaceuticals"},{"orgOrder":0,"company":"Aceragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"||Elongation factor G","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aceragen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Ceftazidim

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : ACG-701 (sodium fusidate) is an investigational oral antibiotic that acts against bacteria by inhibiting an important step in protein synthesis for the treatment of melioidosis.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          June 02, 2023

                          Lead Product(s) : Sodium Fusidate,Ceftazidime

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Zidavi, which is a novel combination of ceftazidime and avibactam, a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae for pyelonephritis or Complicated Urinary Tract Infecti...

                          Product Name : Zidavi

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : Ceftazidime,Avibactam

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          September 28, 2022

                          Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Idera Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 03, 2021

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Arnasi Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 14, 2019

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Allergan

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 01, 2019

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : AbbVie Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 08, 2016

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          University College Cork

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          University College Cork

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Genetic Disease

                          Study Phase : Undisclosed

                          Sponsor : Queen's University, Belfast | Université Paris Cité | University of Dundee | University of Washington | University Hospital Heidelberg | Teagasc | Clininfo | GABO:mi | Papworth Hospital NHS Foundation Trust | KU Leuven | Assistance Publique – Hôpitaux de

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 18, 2015

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Queen's University, Belfast | Université Paris Cité | University of Dundee | University of Washington | University Hospital Heidelberg | Teagasc | Clininfo | GABO:mi | Papworth Hospital NHS Foundation Trust | KU Leuven | Assistance Publique – Hôpitaux de

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 15, 2015

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : PRA Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 19, 2015

                          Lead Product(s) : Ceftazidime

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank